Inventor · disambiguated record
Feng-Jing Chen
Also filed as: CHEN FENG · CHEN FENG-JING
37 granted patents·49 pending applications·8,946 citations·filing 1999–2025
98Inventor score
Files withLIPOCINE INC26EAGLE PHARMACEUTICALS INC16EPALEX CORP11MEMORIAL SLOAN KETTERING CANCER CENTER5CHEN FENG-JING3
Top patents by PatentIndex Score
86 records- 0199US6923988B2Solid carriers for improved delivery of active ingredients in pharmaceutical compositionsLIPOCINE INC·Filed 2003·Granted Aug 2, 2005·857 cites·88 claims
- 0299US6569463B2Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositionsLIPOCINE INC·Filed 2001·Granted May 27, 2003·941 cites·55 claims
- 0399US6451339B2Compositions and methods for improved delivery of hydrophobic agentsLIPOCINE INC·Filed 2001·Granted Sep 17, 2002·514 cites·120 claims
- 0499US6383471B1Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agentsLIPOCINE INC·Filed 1999·Granted May 7, 2002·1k cites·114 claims
- 0599US6309663B1Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agentsLIPOCINE INC·Filed 1999·Granted Oct 30, 2001·561 cites·170 claims
- 0699US6294192B1Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agentsLIPOCINE INC·Filed 1999·Granted Sep 25, 2001·929 cites·74 claims
- 0799US6267985B1Clear oil-containing pharmaceutical compositionsLIPOCINE INC·Filed 1999·Granted Jul 31, 2001·746 cites·184 claims
- 0899US6248363B1Solid carriers for improved delivery of active ingredients in pharmaceutical compositionsLIPOCINE INC·Filed 1999·Granted Jun 19, 2001·1.8k cites·57 claims
- 0998US7374779B2Pharmaceutical formulations and systems for improved absorption and multistage release of active agentsLIPOCINE INC·Filed 2002·Granted May 20, 2008·332 cites·86 claims
- 1098US6761903B2Clear oil-containing pharmaceutical compositions containing a therapeutic agentLIPOCINE INC·Filed 2001·Granted Jul 13, 2004·305 cites·122 claims
- 1198US6720001B2Emulsion compositions for polyfunctional active ingredientsLIPOCINE INC·Filed 1999·Granted Apr 13, 2004·469 cites·21 claims
- 1298US6468559B1Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methodsLIPOCINE INC·Filed 2000·Granted Oct 22, 2002·169 cites·59 claims
- 1397US11207334B1Fospropofol formulationsEPALEX CORP·Filed 2021·Granted Dec 28, 2021·9 cites·21 claims
- 1496US6458383B2Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparinLIPOCINE INC·Filed 2000·Granted Oct 1, 2002·139 cites·94 claims
- 1595US11478490B1Fospropofol formulationsEPALEX CORP·Filed 2021·Granted Oct 25, 2022·3 cites·16 claims
- 1695US6982281B1Pharmaceutical compositions and dosage forms for administration of hydrophobic drugsLIPOCINE INC·Filed 2000·Granted Jan 3, 2006·96 cites·33 claims
- 1794US11439653B1Fospropofol formulationsEPALEX CORP·Filed 2021·Granted Sep 13, 2022·2 cites·7 claims
- 1893US10548989B2Nanoparticle immunoconjugatesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Feb 4, 2020·7 cites·20 claims
- 1992US11628178B2Fospropofol methods and compositionsEPALEX CORP·Filed 2022·Granted Apr 18, 2023·6 cites·32 claims
- 2089US12115164B2Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2023·Granted Oct 15, 2024·0 cites·15 claims
- 2189US11559591B2Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2018·Granted Jan 24, 2023·5 cites·22 claims
- 2288US11744897B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2022·Granted Sep 5, 2023·2 cites·30 claims
- 2388US2023414623A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2488US2023390295A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2584US11793813B2Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2022·Granted Oct 24, 2023·0 cites·9 claims
- 2684US2023000874A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2784US2022409623A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2884US2022409624A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2981US11590077B2Fulvestrant formulations and methods of their useEAGLE PHARMACEUTICALS INC·Filed 2018·Granted Feb 28, 2023·2 cites·56 claims
- 3080US7323439B2Methods and compositions for modulating angiogenesisUNIV LELAND STANFORD JUNIOR·Filed 2001·Granted Jan 29, 2008·8 cites·18 claims
- 3179US2010137271A1Pharmaceutical compositions and dosage forms for administration of hydrophobic drugsLIPOCINE INC·Filed 2009·Application pending·0 cites
- 3276US12397006B2Fospropofol formulationsEPALEX CORP·Filed 2022·Granted Aug 26, 2025·0 cites·18 claims
- 3376US2019201405A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3475US2015064243A1Pharmaceutical compositions and dosage forms for admininistration of hydrophobic drugsLIPOCINE INC·Filed 2014·Application pending·0 cites
- 3575US2024245626A1Propofol compositions and methods of useEPALEX CORP·Filed 2024·Application pending·0 cites
- 3674US11957760B2Folate receptor targeted nanoparticle drug conjugates and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Granted Apr 16, 2024·0 cites·30 claims
- 3774US2023037294A1Nanoparticle immunoconjugatesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2022·Application pending·0 cites
- 3873US2025312361A1Fospropofol methods and compositionsEPALEX CORP·Filed 2025·Application pending·0 cites
- 3972US2018289710A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4071US12377110B2Fospropofol methods and compositionsEPALEX CORP·Filed 2023·Granted Aug 5, 2025·0 cites·32 claims
- 4171US8389730B2Compositions and methods for the treatment of disease associated with TRP-P8 expressionNATARAJAN SATEESH K·Filed 2011·Granted Mar 5, 2013·2 cites·5 claims
- 4271US2020282061A1Pharmaceutical compositions and dosage forms for administration of hydrophobic drugsLIPOCINE INC·Filed 2020·Application pending·0 cites
- 4371US2018264117A1Pharmaceutical compositions and dosage forms for administration of hydrophobic drugsLIPOCINE INC·Filed 2017·Application pending·0 cites
- 4470US2023083749A1Propofol compositions and methods of useEPALEX CORP·Filed 2022·Application pending·0 cites
- 4570US2023241243A1Carrier particle-drug conjugates, self-immolative linkers, and uses thereofELUCIDA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 4670US2023091857A1Fospropofol formulationsEPALEX CORP·Filed 2022·Application pending·0 cites
- 4767US8362264B2Compositions and methods for the treatment of disease associated with Trp-p8 expressionDENDREON CORP·Filed 2004·Granted Jan 29, 2013·2 cites·3 claims
- 4867US2017239250A1Pemetrexed formulationsEAGLE PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4966US12370199B2Fulvestrant formulations and methods of their useEAGLE PHARMACEUTICALS INC·Filed 2021·Granted Jul 29, 2025·0 cites·5 claims
- 5066US2020353096A1Nanoparticle immunoconjugatesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Application pending·0 cites
Showing the top 50 of 86 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Feng-Jing Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →